B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis

Liver International

Volumn 30, Issue 7, 2010, Pages 1059-1066

  Pimenta, Joana ^a,b   Paulo, Cristiana ^a,b   Gomes, André ^a   Silva, Sérgio ^a   Rocha Gonçalves, Francisco ^a,b   Bettencourt, Paulo ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

B type natriuretic peptide; Cardiac output; Cirrhosis; Impedance cardiography; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BLOOD VOLUME; CLINICAL EVALUATION; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEATH; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; FORWARD HEART FAILURE; HEART FUNCTION; HEMODYNAMIC PARAMETERS; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; IMPEDANCE CARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; SYSTOLIC DYSFUNCTION; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; COMPLICATION; HEART DISEASES; HEART OUTPUT; HOSPITALIZATION; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PORTUGAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; VASCULAR RESISTANCE;

AGE FACTORS; BIOLOGICAL MARKERS; CARDIAC OUTPUT; CARDIOGRAPHY, IMPEDANCE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; HEART DISEASES; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INPATIENTS; KAPLAN-MEIERS ESTIMATE; LINEAR MODELS; LIVER CIRRHOSIS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PORTUGAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASCULAR RESISTANCE; KAPLAN-MEIER ESTIMATE;

EID: 77957157909     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02266.x     Document Type: Article

References (30)

1. Passino C, Poletti R, Fontana M. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med 2008, 46:1515-23.
2. Stevenson LW, Maisel AS. Clinical use of natriuretic peptides in the diagnosis and management of heart failure. Cardiovascular Biomarkers: Pathophysiology and Disease Management 2006, 387-40. Morrow DA, In, eds, Totowa, NJ, Humana Press
3. Pimenta J, Paulo C, Mascarenhas J. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol 2009, Epub ahead of print, doi, 10.1016/j.ijcard.2009.08.001
4. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008, 57:268-78.
5. Alqahtani AS, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008, 28:59-69.
6. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009, 3:294-304.
7. Lee SS, Liu H. Cardiovascular determinants of survival in cirrhosis. Gut 2007, 56:746-48.
8. Cazzaniga M, Salerno F, Pagnozzi G. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007 Jun, 56:869-75.
9. Therapondos G, Flapan AD, Plevris JN. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004, 10:1441-53.
10. Ruiz del Arbol L, Urman J, Fernández J. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-8.
11. Wong F, Siu S, Liu P. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001, 101:621-8.
12. Henriksen JH, Gotze JP, Fuglsang S. Increased circulating pro-brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003, 52:1511-7.
13. Yildiz R, Yildirim B, Karincaoglu M. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol 2005, 20:1115-20.
14. Raedle-Hurst TM, Welsch C, Forestier N. Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2008, 20:865-73.
15. Albert NM, Hail MD, Li J. Equivalence of the bioimpedance and thermodilution methods in measuring cardiac output in hospitalized patients with advanced, decompensated chronic heart failure. Am J Crit Care 2004, 13:469-79.
16. Drazner MH, Thompson B, Rosenberg PB. Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2002, 89:993-5.
17. Northridge DB, Findlay IN, Wilson J, Henderson E, Dargie HJ. Non-invasive determination of cardiac output by Doppler echocardiography and electrical bioimpedance. Br Heart J 1990, 63:93-7.
18. Hartleb M, Ruzki K, Karpel E. Cardiovascular status after postural change in compensated cirrhosis: an argument for vasodilatory concept. Liver 1997, 17:1-6.
19. Piscaglia F, Zironi G, Gaiani S. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999, 30:58-64.
20. Helmy A, Jalan R, Newby DE. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001, 33:826-31.
21. Dazzani F, Micati M, Caraceni P. Transthoracic electrical bioimpedance: a non-invasive technique for the evaluation of the haemodynamic alterations in patients with liver cirrhosis. Dig Liver Dis 2005, 37:786-92.
22. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002, 39:S1-266. National Kidney Foundation.
23. Krag A, Bendtsen F, Henriksen JH. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010, 59:105-10.
24. Jiménez W, Arroyo V. Origins of cardiac dysfunction in cirrhosis. Gut 2003, 52:1392-4.
25. Hogenhuis J, Voors AA, Jaarsma T. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005, 7:81-6.
26. Redfield MM, Rodeheffer RJ, Jacobsen SJ. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002, 40:976-82.
27. Wu AH, Omland T, Wold Knudsen C. Breathing not properly multinational study investigations. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the breathing not properly (BNP) multinational study. Am J Hematol 2005, 80:174-80.
28. Knudsen CW, Vik-Mo H, Omland T. Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP). Clin Sci 2005, 109:69-74.
29. Nybo M, Benn M, Mogelvang R. Impact of hemoglobin on plasma pro-B-type natriuretic peptide concentrations in the general population. Clin Chem 2007, 53:1921-7.
30. van Kimmenade RR, Januzzi JL, Baggish AL. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 2006, 48:1621-7.